Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199360383> ?p ?o ?g. }
- W3199360383 endingPage "181" @default.
- W3199360383 startingPage "172" @default.
- W3199360383 abstract "Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT-P13 and subsequently to SB2 (double switch) in patients with IBD. Patients undergoing IFX-double switch in eight Centers in Lombardy (Italy) from November 2018 to May 2019 were retrospectively analyzed. The IFX discontinuation rate, incidence and type of adverse events (AEs), and clinical remission rate were recorded. A comparison with a control group of patients with IBD single-switched from originator IFX to CT-P13 was performed, before and after an inverse probability of treatment weighting (IPTW)-based propensity score analysis. Fifty-two double-switched patients with IBD were enrolled. The 24- and 52-week proportions of patients continuing on IFX therapy following the second switch (CTP13 → SB2) were 98% (95% confidence interval [CI] 94%-100%) and 90% (95% CI 81%-99%), respectively. Four patients experienced a total of five AEs, all graded 1-3 according to Common Terminology Criteria for Adverse Events (CTCAE). No infusion reactions were observed. The 24-week and follow-up end clinical remission rates following the second switch were 94% and 88%, respectively. No differences were observed in the safety and efficacy outcomes by comparing the double-switch group with a single-switch group of 66 patients with IBD; all these results were confirmed by IPTW-adjusted analysis. The study suggests both the safety and efficacy of the double switch from originator IFX to CT-P13 and SB2 in patients with IBD is maintained. This strategy may be associated with potential cost implications." @default.
- W3199360383 created "2021-09-27" @default.
- W3199360383 creator A5005477071 @default.
- W3199360383 creator A5008990417 @default.
- W3199360383 creator A5009719152 @default.
- W3199360383 creator A5019327502 @default.
- W3199360383 creator A5020645078 @default.
- W3199360383 creator A5026747519 @default.
- W3199360383 creator A5031970639 @default.
- W3199360383 creator A5033237781 @default.
- W3199360383 creator A5034882985 @default.
- W3199360383 creator A5039877042 @default.
- W3199360383 creator A5055247546 @default.
- W3199360383 creator A5059243825 @default.
- W3199360383 creator A5059347689 @default.
- W3199360383 creator A5060091163 @default.
- W3199360383 creator A5062361005 @default.
- W3199360383 creator A5063334974 @default.
- W3199360383 creator A5065511179 @default.
- W3199360383 creator A5072928451 @default.
- W3199360383 creator A5076872185 @default.
- W3199360383 creator A5082942631 @default.
- W3199360383 creator A5083412496 @default.
- W3199360383 creator A5088754054 @default.
- W3199360383 date "2021-09-15" @default.
- W3199360383 modified "2023-10-09" @default.
- W3199360383 title "Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study" @default.
- W3199360383 cites W134031355 @default.
- W3199360383 cites W1560551965 @default.
- W3199360383 cites W1940760407 @default.
- W3199360383 cites W2011931673 @default.
- W3199360383 cites W2020859458 @default.
- W3199360383 cites W2022661087 @default.
- W3199360383 cites W2120522488 @default.
- W3199360383 cites W2149858688 @default.
- W3199360383 cites W2153438195 @default.
- W3199360383 cites W2167582510 @default.
- W3199360383 cites W2171297959 @default.
- W3199360383 cites W2174460595 @default.
- W3199360383 cites W2203977709 @default.
- W3199360383 cites W2208243538 @default.
- W3199360383 cites W2342216265 @default.
- W3199360383 cites W2560455300 @default.
- W3199360383 cites W2567453335 @default.
- W3199360383 cites W2578994901 @default.
- W3199360383 cites W2613299853 @default.
- W3199360383 cites W2736727076 @default.
- W3199360383 cites W2767179430 @default.
- W3199360383 cites W2792476042 @default.
- W3199360383 cites W2887206736 @default.
- W3199360383 cites W2896737472 @default.
- W3199360383 cites W2915543214 @default.
- W3199360383 cites W2923675504 @default.
- W3199360383 cites W2984128211 @default.
- W3199360383 cites W3008150080 @default.
- W3199360383 cites W3199360383 @default.
- W3199360383 cites W4210662453 @default.
- W3199360383 cites W4211167126 @default.
- W3199360383 doi "https://doi.org/10.1111/cts.13131" @default.
- W3199360383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34523800" @default.
- W3199360383 hasPublicationYear "2021" @default.
- W3199360383 type Work @default.
- W3199360383 sameAs 3199360383 @default.
- W3199360383 citedByCount "15" @default.
- W3199360383 countsByYear W31993603832021 @default.
- W3199360383 countsByYear W31993603832022 @default.
- W3199360383 countsByYear W31993603832023 @default.
- W3199360383 crossrefType "journal-article" @default.
- W3199360383 hasAuthorship W3199360383A5005477071 @default.
- W3199360383 hasAuthorship W3199360383A5008990417 @default.
- W3199360383 hasAuthorship W3199360383A5009719152 @default.
- W3199360383 hasAuthorship W3199360383A5019327502 @default.
- W3199360383 hasAuthorship W3199360383A5020645078 @default.
- W3199360383 hasAuthorship W3199360383A5026747519 @default.
- W3199360383 hasAuthorship W3199360383A5031970639 @default.
- W3199360383 hasAuthorship W3199360383A5033237781 @default.
- W3199360383 hasAuthorship W3199360383A5034882985 @default.
- W3199360383 hasAuthorship W3199360383A5039877042 @default.
- W3199360383 hasAuthorship W3199360383A5055247546 @default.
- W3199360383 hasAuthorship W3199360383A5059243825 @default.
- W3199360383 hasAuthorship W3199360383A5059347689 @default.
- W3199360383 hasAuthorship W3199360383A5060091163 @default.
- W3199360383 hasAuthorship W3199360383A5062361005 @default.
- W3199360383 hasAuthorship W3199360383A5063334974 @default.
- W3199360383 hasAuthorship W3199360383A5065511179 @default.
- W3199360383 hasAuthorship W3199360383A5072928451 @default.
- W3199360383 hasAuthorship W3199360383A5076872185 @default.
- W3199360383 hasAuthorship W3199360383A5082942631 @default.
- W3199360383 hasAuthorship W3199360383A5083412496 @default.
- W3199360383 hasAuthorship W3199360383A5088754054 @default.
- W3199360383 hasBestOaLocation W31993603831 @default.
- W3199360383 hasConcept C126322002 @default.
- W3199360383 hasConcept C141071460 @default.
- W3199360383 hasConcept C17923572 @default.
- W3199360383 hasConcept C197934379 @default.
- W3199360383 hasConcept C207103383 @default.
- W3199360383 hasConcept C2777138892 @default.
- W3199360383 hasConcept C2777793932 @default.